The question ahead of the interims
Accsys Technologies (LSE:AXS), which makes Accoya acetylated wood in Arnhem and, through a joint venture, in Tennessee, reports interim results for the six months to 30 September 2026 at 07:00 GMT on 24 November. Its only announcement since was the 10 November notice of that date. With trading softer than planned earlier in the financial year, a less discussed issue is how comfortably the Balance Sheet absorbs lower volumes. This piece draws on the 16 June annual results and the 21 September trading update; all figures are in euros.
What the balance sheet looked like in March
At 31 March 2026, net Debt was €41.4m, down from €42.6m a year earlier. The company calculated leverage, defined as net debt to underlying EBITDA, at 1.96 times, against 2.52 times in FY25 and 4.35 times in March 2024. Stripping out the convertible Loan notes, Leverage was 0.74 times. Underlying EBITDA for FY26 was €21.1m and free Cash Flow was €10.2m.
In October 2025 Accsys (LSE:AXS) replaced its bank debt with €55m of facilities split equally between ABN AMRO and HSBC: a €20m term loan and a €35m revolving Credit facility, maturing in October 2028 with a possible one-year extension at the banks' discretion. Management said the new terms should improve annual cash flow by about €2m. Separately, €21m of six-year unsecured convertible notes issued in November 2023 carry a fixed 9.5% coupon. In July 2026 two holders took €2.5m of rolled-up interest as 3,004,085 new shares, which the company said improved net debt.
The stress test worth revisiting
The Going Concern note in the annual results disclosed a reverse stress test. The company said group sales volumes would need to fall by more than roughly 13.4% against the prior year, or by more than about 28.5% against its base case, before bank covenants were breached during the assessment period. It added that it could defer discretionary Capital spending and cut costs if needed, and said it did not expect that scenario to occur.
The September update showed group volumes of 22,186 cubic metres in the five months to 31 August, 11% below the same period a year earlier, while joint venture volumes rose 3%. Group Revenue fell 6% to €56.9m. The company blamed distributor destocking, particularly in North America, and said it believed destocking had ended, with September trading firmer. The five-month Volume decline sits not far from the 13.4% threshold, although the test applies across a full assessment period, and the company said it expects H1 comparisons to improve and H2 sales to grow.
Why it matters
Guidance has already moved. The board expects FY27 adjusted EBITDA of €21m to €23m, against consensus of €28.8m that the company quoted at 18 September, while underlying EBITDA, excluding the joint venture, is expected broadly in line with €24.5m consensus. Lower Earnings would raise the Leverage Ratio mechanically even if net debt stays flat. The leverage target in the first phase of its FOCUS strategy only requires a reduction from the 4.35 times recorded in March 2024, so a modest rise would not break it, but it would interrupt the deleveraging story.
Factors to watch
Accsys (LSE:AXS) has a contractual obligation to fund 60% of Accoya USA alongside Eastman, and the joint venture carries its own US bank borrowings. Price increases, cost control and a second-half weighting all need to deliver. The company has not disclosed covenant levels or headroom since March, so the interim statement is the first chance to see updated figures.
Dates to watch
Results arrive on 24 November with a 09:00 GMT webcast, followed by an Investor Meet Company presentation on 2 December at 16:30 GMT. Investors will look for net debt, leverage, Working Capital and any revised view of covenant headroom.



_11_17_2026_12_23_17_880745.jpg)


Please wait processing your request...